| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.03% | 1,248,507 | TRIMMED (-8.8%) |
| Polen Capital Management | 0.01% | 70,292 | TRIMMED (-7.1%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end.
1 insiders bought on the open market in the last 90 days (1 purchases, $50.0K), against 0 sales by 0 insiders ($0). Latest buy: Aug 6, 2026.
CEO/CFO boughtSource: SEC Form 4 filings, as of Oct 3, 2026. Open-market transactions only.
Data unavailable — no House STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
Insiders
· CEO & CFO Buying — Last 90 days: top executives (CEO/CFO) bought on the open market
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Dividend Growth — Dividends raised for more than 10 years
Red Flags
· Financial Restatement (8-K 4.02) — Last 3 years: a non-reliance / restatement filing (8-K Item 4.02)
· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)
Key figures
· Dividend Growth — Dividend per share: 0.09 · Dividend yield: 1.3% · Straight dividend years: 5 · 10-yr dividend growth: —
· CEO & CFO Buying — Buy txns: 1 · Buy value: $50.0K · Insiders buying: 1 · Latest buy: Aug 6, 2026
· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $50.0K · Latest buy: Aug 6, 2026
· Financial Restatement (8-K 4.02) — Latest event: May 13, 2025 · Events in 3 yrs: 2
· Late Filings (NT) — Latest event: May 13, 2025 · Events in 2 yrs: 1 · Latest form: NT 10-Q
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2025 Q4, ranked #30 of 50.
Open this in the GetCoattail app →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.